1. Clinical Overview
A fixed-dose combination of a typical antipsychotic (trifluoperazine) and an anticholinergic/antispasmodic agent (isopropamide). Trifluoperazine is a high-potency piperazine phenothiazine that acts as a dopamine D2 receptor antagonist, primarily used for its antipsychotic and antiemetic properties. Isopropamide iodide is a quaternary ammonium antimuscarinic agent that reduces gastrointestinal motility and secretions. This combination is primarily used to manage psychosomatic disorders, particularly those with significant gastrointestinal symptoms like peptic ulcer, irritable bowel syndrome, and functional dyspepsia, where anxiety and hypermotility are intertwined. Its use has declined with the advent of newer, safer antipsychotics and a better understanding of psychosomatic medicine.
| Onset | Duration | Bioavailability |
|---|---|---|
| Trifluoperazine: Psychotic symptoms may take 2-3 weeks for full effect, but sedation and antiemetic action occur within 30-60 minutes. Isopropamide: Antispasmodic effects begin within 1-2 hours. | Trifluoperazine: Single dose effects last 4-6 hours, but with chronic dosing, antipsychotic effects are sustained. Isopropamide: Effects last 10-12 hours due to its long half-life. | Trifluoperazine: Approximately 50-60% orally due to significant first-pass metabolism. Isopropamide: Poorly absorbed from the GI tract (<10%) as a quaternary ammonium compound; acts locally. |
2. Mechanism of Action
The combination works via two distinct mechanisms. Trifluoperazine exerts its primary antipsychotic effect by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway of the brain. Its antiemetic action is via blockade of D2 receptors in the chemoreceptor trigger zone (CTZ). The anticholinergic action of isopropamide blocks muscarinic acetylcholine receptors (M1, M3) in the gastrointestinal tract, reducing smooth muscle contractions (motility) and secretory activity (acid, enzymes). In the CNS, isopropamide's weak central anticholinergic action may help mitigate some extrapyramidal symptoms caused by trifluoperazine.
3. Indications & Uses
- Psychosomatic disorders with predominant gastrointestinal symptoms (e.g., irritable bowel syndrome, functional dyspepsia)
- Anxiety-associated gastrointestinal hypermotility and spasm
- Adjuvant therapy in peptic ulcer disease (historical use, not current standard)
4. Dosage & Administration
Adult Dosage: One tablet (Isopropamide 5mg + Trifluoperazine 2mg) twice daily, usually after meals. Maximum: 3 tablets per day. Therapy should be initiated at the lowest effective dose for the shortest possible duration.
Administration: Administer orally with or after food to minimize gastric irritation. Tablet should be swallowed whole with a full glass of water. Do not crush or chew. Avoid antacids within 2 hours of administration as they may interfere with absorption of trifluoperazine.
5. Side Effects
Common side effects may include:
- Dry mouth (xerostomia)
- Blurred vision
- Constipation
- Drowsiness/sedation
- Dizziness
- Postural hypotension
- Weight gain
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive CNS depression, respiratory depression, sedation | Major |
| Anticholinergic Drugs (Atropine, Tricyclic Antidepressants, Antihistamines) | Additive anticholinergic toxicity: severe dry mouth, constipation, urinary retention, hyperthermia, confusion | Major |
| Levodopa, Dopamine Agonists | Mutual antagonism; reduced efficacy of both drugs | Major |
| QT-prolonging drugs (Class Ia/III antiarrhythmics, Macrolides, Fluoroquinolones) | Increased risk of life-threatening cardiac arrhythmias (torsades de pointes) | Major |
| Epinephrine | Trifluoperazine may reverse pressor effect, leading to paradoxical hypotension | Moderate |
| Antihypertensives | Potentiation of hypotensive effects | Moderate |
| Lithium | Increased risk of neurotoxicity (encephalopathy) and extrapyramidal symptoms | Major |
| SSRIs (especially Fluoxetine, Paroxetine - CYP2D6 inhibitors) | Increased plasma levels of trifluoperazine, leading to toxicity | Moderate |
7. Patient Counselling
- DO take exactly as prescribed by your doctor. Do not increase dose.
- DO take with food if stomach upset occurs.
- DO report any involuntary movements of face/tongue/limbs immediately.
- DO rise slowly from sitting/lying position to avoid dizziness.
- DO maintain good oral hygiene to manage dry mouth (sugar-free gum/candies).
- DONT stop taking this medicine suddenly without consulting your doctor.
- DONT consume alcohol in any form.
- DONT drive or operate machinery until you know how the medicine affects you.
- DONT take over-the-counter cold, allergy, or sleep aids without consulting your doctor (may contain anticholinergics).
- DONT expose skin to direct sunlight for prolonged periods; use sunscreen.
8. Toxicology & Storage
Overdose: Primarily an extension of side effects: Severe CNS depression (coma), hypotension, tachycardia, cardiac arrhythmias (QT prolongation, torsades), anticholinergic crisis (hyperthermia, hot dry skin, flushed face, dilated pupils, ileus, urinary retention), agitation, seizures, extrapyramidal symptoms, neuroleptic malignant syndrome.
Storage: Store below 30°C in a cool, dry place, protected from light and moisture. Keep the container tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.